| 著者 | 松岡 順治| 田渕 陽子| 伊藤 充矢| 小野 亮子| 今田 孝子| 松川 啓義| 元木 崇之| 猶本 良夫| 金澤 右| |
|---|---|
| 発行日 | 2006-09-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 118巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 今田 孝子| 松岡 順治| 元木 崇之| 岩本 高行| 大森 昌子| 伊波 茂道| 本後 登志江| 逸見 典子| 真壁 幹夫| 野上 浩實| |
|---|---|
| 発行日 | 2012-12-03 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 3号 |
| 資料タイプ | 学術雑誌論文 |
| タイトル（別表記） | Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer |
|---|---|
| フルテキストURL | 126_25.pdf |
| 著者 | 溝尾 妙子| 枝園 忠彦| 伊藤 麻衣子| 野上 智弘| 岩本 高行| 元木 崇之| 平 成人| 松岡 順治| 土井原 博義| |
| 抄録 | Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay. Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection. Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected. Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery. |
| キーワード | OSNA法（OSNA method） センチネルリンパ節（sentinel lymph node） micrometastases CK-19 |
| 出版物タイトル | 岡山医学会雑誌 |
| 発行日 | 2014-04-01 |
| 巻 | 126巻 |
| 号 | 1号 |
| 開始ページ | 25 |
| 終了ページ | 30 |
| ISSN | 0030-1558 |
| 関連URL | http://www.okayama-u.ac.jp/user/oma/ |
| 言語 | 日本語 |
| 著作権者 | Copyright (c) 2014 岡山医学会 |
| 論文のバージョン | publisher |
| DOI | 10.4044/joma.126.25 |
| 著者 | 松岡 順治| 田渕 陽子| 小野 亮子| 今田 孝子| 梅岡 達生| 渡辺 直樹| 元木 崇之| 松川 啓義| 猶本 良夫| 田中 紀章| 柳井 広之| 大森 昌子| |
|---|---|
| 発行日 | 2006-09-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 118巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 松岡 順治| 田渕 陽子| 伊藤 充矢| 小野 亮子| 今田 孝子| 元木 崇之| 松川 啓義| 大森 昌子| 柳井 広之| 猶本 良夫| 田中 紀章| |
|---|---|
| 発行日 | 2006-09-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 118巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| JaLCDOI | 10.18926/AMO/64356 |
|---|---|
| フルテキストURL | 77_1_11.pdf |
| 著者 | Watanabe, Satoko| Saiga, Miho| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Doihara, Hiroyoshi| Kimata, Yoshihiro| |
| 抄録 | The importance of a well-fitted, comfortable brassiere to overall quality of life after breast reconstruction has not been evaluated. Our aim was to determine the impact of a semi-customized brassiere on patients’ health-related quality of life after breast reconstruction. The subjects were prospective patients with mastectomy who were to undergo immediate or delayed breast reconstruction at our hospital. After surgery, a professional bra fitter sized each patient for a semi-customized brassiere and provided follow-up consultations. A self-reported questionnaire on breast aesthetics, postoperative pain, and satisfaction was used to assess the primary outcomes. Data were prospectively collected at baseline (before surgery) and at 1, 3, 6, and 12 months after surgery and analyzed. Forty-six patients (50 breasts) were included in the analysis. Consistent wearing of the brassiere reduced pain (p<0.05), with good overall satisfaction (p<0.001). Aesthetic scores on breast shape and size were higher with than without the custom brassiere at 3 months (p=0.02) and 6 months (p=0.03) after surgery. Wearing the brassiere reduced anxiety at all time points of measurement. A well-fitting brassiere ensured safety and provided a high degree of satisfaction without anxiety for patients after breast reconstruction. |
| キーワード | breast reconstruction mastectomy brassiere professional bra fitter |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2023-02 |
| 巻 | 77巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 11 |
| 終了ページ | 19 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2023 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36849141 |
| Web of Science KeyUT | 000953663800002 |
| JaLCDOI | 10.18926/AMO/53675 |
|---|---|
| フルテキストURL | 69_5_291.pdf |
| 著者 | Sugiu, Kumi| Iwamoto, Takayuki| Kelly, Catherine M.| Watanabe, Naoki| Motoki, Takayuki| Itoh, Mitsuya| Ohtani, Shoichiro| Higaki, Kenji| Imada, Takako| Yuasa, Takeshi| Omori, Masako| Sonobe, Hiroshi| Fujiwara, Toshiyoshi| Matsuoka, Junji| |
| 抄録 | Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies. |
| キーワード | breast cancer neoadjuvant chemotherapy concurrent hormone therapy estrogen receptor positive tumor response |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2015-10 |
| 巻 | 69巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 291 |
| 終了ページ | 299 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2015 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 26490026 |
| Web of Science KeyUT | 000365519600005 |
| 著者 | 渡辺 信之| 髙岡 宗徳| 櫻間 一史| 友野 靖子| 畠山 慎二| 大森 修| 元木 崇之| 白川 靖博| 山辻 知樹| 羽井佐 実| 松岡 順治| Beer, David G.| 長塚 仁| 田中 紀章| 猶本 良夫| |
|---|---|
| 発行日 | 2010-04-01 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 122巻 |
| 号 | 1号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos| |
|---|---|
| 発行日 | 2014-01 |
| 出版物タイトル | Breast Cancer Research and Treatment |
| 巻 | 143巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro| |
|---|---|
| 発行日 | 2013-12-01 |
| 出版物タイトル | BMC Cancer |
| 巻 | 13巻 |
| 資料タイプ | 学術雑誌論文 |
| JaLCDOI | 10.18926/AMO/53907 |
|---|---|
| フルテキストURL | 69_6_333.pdf |
| 著者 | Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro| |
| 抄録 | We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients. |
| キーワード | breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2015-12 |
| 巻 | 69巻 |
| 号 | 6号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 333 |
| 終了ページ | 338 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2015 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 26690243 |
| Web of Science KeyUT | 000368434500002 |
| JaLCDOI | 10.18926/AMO/50407 |
|---|---|
| フルテキストURL | 67_3_145.pdf |
| 著者 | Ishihara, Setsuko| Taira, Naruto| Kawasaki, Kensuke| Ishibe, Youichi| Mizoo, Taeko| Nishiyama, Keiko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Komoike, Yoshifumi| Sato, Shuhei| Kanazawa, Susumu| |
| 抄録 | A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, －0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, －0.196;p value, 0.0143) and number of deliveries (parameter estimate, －0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s. |
| キーワード | breast cancer mammographic breast density life style body mass index |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2013-06 |
| 巻 | 67巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 145 |
| 終了ページ | 151 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2013 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 23804137 |
| Web of Science KeyUT | 000320747900003 |
| 関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/50646 |
| 著者 | Nishikawa, Toshio| Takaoka, Munenori| Ohara, Toshiaki| Tomono, Yasuko| Hao, Huifang| Bao, Xiaohong| Fukazawa, Takuya| Wang, Zhigang| Sakurama, Kazufumi| Fujiwara, Yasuhiro| Motoki, Takayuki| Shirakawa, Yasuhiro| Yamatsuji, Tomoki| Tanaka, Noriaki| Fujiwara, Toshiyoshi| Naomoto, Yoshio| |
|---|---|
| 発行日 | 2013-03 |
| 出版物タイトル | Cancer Biology & Therapy |
| 巻 | 14巻 |
| 号 | 3号 |
| 資料タイプ | 学術雑誌論文 |
| JaLCDOI | 10.18926/AMO/54607 |
|---|---|
| フルテキストURL | 70_5_425.pdf |
| 著者 | Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| |
| 抄録 | Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer. |
| キーワード | breast cancer phase I trial docetaxel |
| Amo Type | Clinical Study Protocols |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2016-10 |
| 巻 | 70巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 425 |
| 終了ページ | 427 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2016 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 27777441 |
| Web of Science KeyUT | 000388098700018 |